DNA methylation and gene silencing in cancer
- PMID: 16341240
- DOI: 10.1038/ncponc0354
DNA methylation and gene silencing in cancer
Abstract
Epigenetic changes such as DNA methylation act to regulate gene expression in normal mammalian development. However, promoter hypermethylation also plays a major role in cancer through transcriptional silencing of critical growth regulators such as tumor suppressor genes. Other chromatin modifications, such as histone deacetylation and chromatin-binding proteins, affect local chromatin structure and, in concert with DNA methylation, regulate gene transcription. The DNA methylation inhibitors azacitidine and decitabine can induce functional re-expression of aberrantly silenced genes in cancer, causing growth arrest and apoptosis in tumor cells. These agents, along with inhibitors of histone deacetylation, have shown clinical activity in the treatment of certain hematologic malignancies where gene hypermethylation occurs. This review examines alteration in DNA methylation in cancer, effects on gene expression, and implications for the use of hypomethylating agents in the treatment of cancer.
Similar articles
-
Reactivating the expression of methylation silenced genes in human cancer.Oncogene. 2002 Aug 12;21(35):5496-503. doi: 10.1038/sj.onc.1205602. Oncogene. 2002. PMID: 12154410 Review.
-
Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.Ann Hematol. 2005 Dec;84 Suppl 1:54-60. doi: 10.1007/s00277-005-0006-z. Ann Hematol. 2005. PMID: 16228241
-
Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine.Cancer Res. 2002 Nov 15;62(22):6456-61. Cancer Res. 2002. PMID: 12438235
-
Demethylation of DNA by decitabine in cancer chemotherapy.Expert Rev Anticancer Ther. 2004 Aug;4(4):501-10. doi: 10.1586/14737140.4.4.501. Expert Rev Anticancer Ther. 2004. PMID: 15270655 Review.
-
DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.Haematologica. 2002 Dec;87(12):1324-41. Haematologica. 2002. PMID: 12495905 Review.
Cited by
-
Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review.Front Oncol. 2024 Jul 26;14:1405267. doi: 10.3389/fonc.2024.1405267. eCollection 2024. Front Oncol. 2024. PMID: 39132504 Free PMC article.
-
Structural basis for the H2AK119ub1-specific DNMT3A-nucleosome interaction.Nat Commun. 2024 Jul 23;15(1):6217. doi: 10.1038/s41467-024-50526-3. Nat Commun. 2024. PMID: 39043678 Free PMC article.
-
Increased ONECUT2 induced by Helicobacter pylori promotes gastric cancer cell stemness via an AKT-related pathway.Cell Death Dis. 2024 Jul 12;15(7):497. doi: 10.1038/s41419-024-06885-2. Cell Death Dis. 2024. PMID: 38997271 Free PMC article.
-
Trichostatin C Synergistically Interacts with DNMT Inhibitor to Induce Antineoplastic Effect via Inhibition of Axl in Bladder and Lung Cancer Cells.Pharmaceuticals (Basel). 2024 Mar 27;17(4):425. doi: 10.3390/ph17040425. Pharmaceuticals (Basel). 2024. PMID: 38675387 Free PMC article.
-
Vpr driving DNA methylation variation of CD4 + T cells in HIV-1 infection.Virol J. 2024 Apr 26;21(1):97. doi: 10.1186/s12985-024-02363-5. Virol J. 2024. PMID: 38671522 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources